Picture of Circio Holding ASA logo

CRNA Circio Holding ASA Share Price

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-54.65%
3m-60.05%
6m-65.14%
1yr-85.81%
Volume Change (%)
10d/3m+262.25%
Price vs... (%)
52w High-88.74%
50d MA-51.11%
200d MA-70.69%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-299.84%
Operating Margin-5062.22%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Circio Holding ASA EPS forecast chart

Profile Summary

Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
November 9th, 2010
Public Since
June 16th, 2014
No. of Shareholders
6,522
No. of Employees
21
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
no flag iconOslo Stock Exchange
Shares in Issue
7,163,743
Blurred out image of a map
Address
Vollsveien 19, LYSAKER, 1366
Web
https://www.circio.com/en/
Phone
+47 21398810
Auditors
PricewaterhouseCoopers AS

CRNA Share Price Performance

Upcoming Events for CRNA

Q1 2024 Targovax ASA Earnings Release

Targovax ASA Annual Shareholders Meeting

Circio Holding ASA Annual Shareholders Meeting

Half Year 2024 Circio Holding ASA Earnings Release

Similar to CRNA

Picture of Arcticzymes Technologies ASA logo

Arcticzymes Technologies ASA

no flag iconOslo Stock Exchange

Picture of Bergenbio ASA logo

Bergenbio ASA

no flag iconOslo Stock Exchange

Picture of Exact Therapeutics AS logo

Exact Therapeutics AS

no flag iconOslo Stock Exchange

Picture of Lifecare AS logo

Lifecare AS

no flag iconOslo Stock Exchange

Picture of Lytix Biopharma AS logo

Lytix Biopharma AS

no flag iconOslo Stock Exchange

FAQ